Richard C. Ahrens

4.0k total citations · 2 hit papers
60 papers, 2.8k citations indexed

About

Richard C. Ahrens is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Richard C. Ahrens has authored 60 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 37 papers in Physiology and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Richard C. Ahrens's work include Asthma and respiratory diseases (36 papers), Inhalation and Respiratory Drug Delivery (32 papers) and Cystic Fibrosis Research Advances (21 papers). Richard C. Ahrens is often cited by papers focused on Asthma and respiratory diseases (36 papers), Inhalation and Respiratory Drug Delivery (32 papers) and Cystic Fibrosis Research Advances (21 papers). Richard C. Ahrens collaborates with scholars based in United States, Canada and France. Richard C. Ahrens's co-authors include Miles Weinberger, Paula Anderson, Myrna Dolovich, Gerald C. Smaldone, Gordon Guyatt, Dean Hess, Joseph L. Rau, Rajiv Dhand, William Smits and Michael McCubbin and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Richard C. Ahrens

59 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines

2005 593 citations Richard C. Ahrens, Paula Anderson et al. CHEST Journal profile →
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

2013 369 citations Jane C. Davies, Claire Wainwright et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard C. Ahrens United States	25	2.4k	1.1k	244	164	157	60	2.8k
H Matthys Germany	33	2.3k 1.0×	1.8k 1.6×	267 1.1×	195 1.2×	72 0.5×	219	3.8k
EF Wouters Netherlands	26	2.0k 0.8×	1.4k 1.3×	231 0.9×	164 1.0×	59 0.4×	48	2.9k
Evangelia Daviskas Australia	31	2.6k 1.1×	1.3k 1.2×	117 0.5×	188 1.1×	39 0.2×	52	3.0k
Alexander Mœller Switzerland	27	1.7k 0.7×	919 0.8×	323 1.3×	253 1.5×	99 0.6×	113	2.9k
Richard Kraemer Switzerland	23	1.7k 0.7×	433 0.4×	121 0.5×	233 1.4×	130 0.8×	77	2.0k
Paul Dorinsky United States	34	3.3k 1.4×	2.9k 2.6×	199 0.8×	374 2.3×	171 1.1×	162	4.2k
А. Г. Чучалин Russia	28	2.0k 0.8×	1.5k 1.4×	258 1.1×	406 2.5×	189 1.2×	237	3.1k
Patrick Lebecque Belgium	31	1.9k 0.8×	718 0.6×	448 1.8×	367 2.2×	101 0.6×	99	3.0k
Ari Lindqvist Finland	28	1.2k 0.5×	972 0.9×	89 0.4×	227 1.4×	80 0.5×	92	2.2k
Mauro Carone Italy	26	1.6k 0.7×	616 0.6×	131 0.5×	159 1.0×	48 0.3×	91	2.1k

Countries citing papers authored by Richard C. Ahrens

Since Specialization

Citations

This map shows the geographic impact of Richard C. Ahrens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Ahrens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Ahrens more than expected).

Fields of papers citing papers by Richard C. Ahrens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard C. Ahrens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Ahrens. The network helps show where Richard C. Ahrens may publish in the future.

Co-authorship network of co-authors of Richard C. Ahrens

This figure shows the co-authorship network connecting the top 25 collaborators of Richard C. Ahrens. A scholar is included among the top collaborators of Richard C. Ahrens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard C. Ahrens. Richard C. Ahrens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allan, Richard, et al.. (2019). A Dose-Response Study Examining the Use of Methacholine Challenge to Demonstrate Local Therapeutic Equivalence of the Salmeterol Component of Generic Inhaled Fluticasone Propionate/Salmeterol Combination Products. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 32(6). 352–363. 1 indexed citations

Zemanick, Edith T., Brandie D. Wagner, Charles E. Robertson, et al.. (2017). Airway microbiota across age and disease spectrum in cystic fibrosis. European Respiratory Journal. 50(5). 1700832–1700832. 159 indexed citations

Heubi, James E., David J. Schaeffer, Richard C. Ahrens, et al.. (2016). Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial. The Journal of Pediatrics. 176. 156–161.e1. 15 indexed citations

Mondal, Pritish, et al.. (2014). Nonprescription Racemic Epinephrine for Asthma. The Journal of Allergy and Clinical Immunology In Practice. 2(5). 575–578. 5 indexed citations

Davies, Jane C., Claire Wainwright, Gerard J. Canny, et al.. (2013). Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation. American Journal of Respiratory and Critical Care Medicine. 187(11). 1219–1225. 369 indexed citations breakdown →

Konstan, Michael W., Frank J. Accurso, Samya Z. Nasr, Richard C. Ahrens, & Gavin R. Graff. (2013). Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis. Clinical Investigation. 3(8). 723–729. 12 indexed citations

Shuster, Jonathan J., et al.. (2011). Methacholine Challenge as a Clinical Bioassay of Pulmonary Delivery of a Long‐Acting β₂‐Adrenergic Agonist. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 31(5). 449–457. 10 indexed citations

Drummond, Michael, Pamela F. Schwartz, William Duggan, et al.. (2008). Intersession Variability in Single-Breath Diffusing Capacity in Diabetics without Overt Lung Disease. American Journal of Respiratory and Critical Care Medicine. 178(3). 225–232. 17 indexed citations

Moss, Richard B., Nicole Mayer‐Hamblett, Jeffrey S. Wagener, et al.. (2004). Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Study of Aerosolized Interferon Gamma‐1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease. Pediatric Pulmonology. 39(3). 209–218. 47 indexed citations

10.

Chrischilles, Elizabeth A., Richard C. Ahrens, Kevin M. Kelly, et al.. (2004). Asthma prevalence and morbidity among rural Iowa schoolchildren. Journal of Allergy and Clinical Immunology. 113(1). 66–71. 65 indexed citations

11.

Asmus, Michael J., B. A. Stewart, M. Teresi, et al.. (2002). Tobramycin as a Pharmacologic Tracer to Compare Airway Deposition from Nebulizers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 22(5). 557–563. 9 indexed citations

12.

Ahrens, Richard C., et al.. (2001). Asthma Stability After Oral Prednisone. American Journal of Respiratory and Critical Care Medicine. 164(7). 1138–1145. 12 indexed citations

13.

Geoffroy, Pierre A., Richard L. Lalonde, Richard C. Ahrens, et al.. (1999). Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma. Annals of Allergy Asthma & Immunology. 82(4). 377–382. 15 indexed citations

14.

Ahrens, Richard C., et al.. (1999). Therapeutic Equivalence of Spiros Dry Powder Inhaler and Ventolin Metered Dose Inhaler: A Bioassay Using Methacholine. American Journal of Respiratory and Critical Care Medicine. 160(4). 1238–1243. 27 indexed citations

15.

McCubbin, Michael, et al.. (1995). A bioassay for topical and systemic effect of three inhaled corticosteroids*. Clinical Pharmacology & Therapeutics. 57(4). 455–460. 32 indexed citations

16.

Ahrens, Richard C., et al.. (1995). Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: Evidence that the specific drug being delivered is an important consideration. Journal of Allergy and Clinical Immunology. 96(2). 288–294. 66 indexed citations

17.

Harris, James B., et al.. (1990). Comparison of the intensity and duration of effects of inhaled bitolterol and albuterol on airway caliber and airway responsiveness to histamine. Journal of Allergy and Clinical Immunology. 85(6). 1043–1049. 5 indexed citations

18.

Ahrens, Richard C.. (1990). Skeletal Muscle Tremor and the Influence of Adrenergic Drugs. Journal of Asthma. 27(1). 11–20. 17 indexed citations

19.

Ahrens, Richard C., et al.. (1987). The Effect of Theophylline and β2 Agonists on Airway Reactivity. CHEST Journal. 92(1). 15S–21S. 1 indexed citations

20.

Weinberger, Miles, Leslie Hendeles, & Richard C. Ahrens. (1981). Clinical Pharmacology of Drugs Used for Asthma. Pediatric Clinics of North America. 28(1). 47–75. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact